Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 displays perfect anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 223.00 | |
25 mg | In stock | $ 1,280.00 | |
50 mg | In stock | $ 1,670.00 | |
100 mg | In stock | $ 2,530.00 |
Description | DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 displays perfect anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype. |
In vitro | DRF-1042 shows superior lactone stability and good in vitro anticancer activity. It can against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype [2]. |
In vivo | DRF-1042 treatment displays poor myelosuppression, in clonogenic assay against murine, canine, and human bone marrow cells. Which supports the possibility of protracted dose schedule in both experimental and clinical studies [2]. |
Molecular Weight | 408.4 |
Formula | C22H20N2O6 |
CAS No. | 200619-13-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (122.43 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DRF-1042 200619-13-2 Others DRF 1042 DRF1042 inhibitor inhibit